ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 151 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,247,000 | +5.4% | 37,209 | -16.3% | 0.00% | 0.0% |
| Q3 2016 | $1,183,000 | +18.1% | 44,464 | -2.2% | 0.00% | 0.0% |
| Q2 2016 | $1,002,000 | -32.5% | 45,457 | -10.0% | 0.00% | -50.0% |
| Q1 2016 | $1,484,000 | -0.4% | 50,519 | +12.0% | 0.00% | 0.0% |
| Q4 2015 | $1,490,000 | -22.7% | 45,112 | -15.5% | 0.00% | 0.0% |
| Q3 2015 | $1,928,000 | -23.1% | 53,358 | -4.3% | 0.00% | -33.3% |
| Q2 2015 | $2,508,000 | -3.8% | 55,751 | -34.5% | 0.00% | 0.0% |
| Q1 2015 | $2,606,000 | -11.0% | 85,104 | +47.8% | 0.00% | 0.0% |
| Q4 2014 | $2,928,000 | +5.4% | 57,586 | -18.0% | 0.00% | 0.0% |
| Q3 2014 | $2,779,000 | +53.6% | 70,230 | +67.2% | 0.00% | +50.0% |
| Q2 2014 | $1,809,000 | +2219.2% | 42,004 | +2050.7% | 0.00% | – |
| Q1 2014 | $78,000 | +50.0% | 1,953 | +3.1% | 0.00% | – |
| Q4 2013 | $52,000 | +15.6% | 1,894 | -4.0% | 0.00% | – |
| Q3 2013 | $45,000 | -94.2% | 1,973 | -95.5% | 0.00% | -100.0% |
| Q2 2013 | $779,000 | – | 43,998 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |